...
首页> 外文期刊>Journal of Molecular Diagnostics >Establishment and Study of Different Real-Time Polymerase Chain Reaction Assays for the Quantification of Cells with Deletions of Chromosome 7
【24h】

Establishment and Study of Different Real-Time Polymerase Chain Reaction Assays for the Quantification of Cells with Deletions of Chromosome 7

机译:用于定量删除7号染色体的不同实时聚合酶链反应测定方法的建立和研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The evaluation of residual disease, which has prognostic value in the treatment of hematological malignancies, is currently assessed by scoring a limited number of cells by karyotyping and molecular cytogenetics. Real-time polymerase chain reaction (PCR) is an easier and more sensitive technique, enables analysis of a larger number of cells, and decreases sampling error. However, real-time PCR has been applied only to target transcripts of fusion genes. Here, we considered two real-time PCR strategies to quantify a number of cells carrying a partial deletion of chromosome 7 mixed with normal disomic cells. The first strategy was based on the amplification of two sequences, one on chromosome 7 and the other on chromosome 14. In the second strategy residual disease was assessed by the ratio between the two alleles of a bi-allelic marker, mapped on chromosome 7, measured with allele-specific assays. Precision and accuracy of the two approaches were tested by reference samples with nominal values of residual disease ranging from 2 to 95%. As expected the second strategy resulted in more precise and accurate monitoring within the range from 5 to 95%. Furthermore, this method may be applied to assess the number of dysplastic or neoplastic clones carrying any unbalanced chromosome changes.
机译:目前,通过核型分析和分子细胞遗传学对有限数量的细胞进行评分,可以评估残留疾病的价值,该疾病在血液系统恶性肿瘤的治疗中具有预后价值。实时聚合酶链反应(PCR)是一种更轻松,更灵敏的技术,可以分析大量细胞,并减少采样误差。但是,实时PCR仅应用于融合基因的目标转录本。在这里,我们考虑了两种实时PCR策略来量化与正常二体细胞混合的携带7号染色体部分缺失的细胞数量。第一种策略是基于两个序列的扩增,一个序列位于7号染色体上,另一个序列位于14号染色体上。在第二种策略中,通过绘制在7号染色体上的双等位基因标记的两个等位基因之间的比率来评估残留疾病。用等位基因特异性测定法测定。两种方法的精度和准确性均通过参考样本进行了测试,残留疾病的标称值为2%至95%。不出所料,第二种策略可以在5%到95%的范围内进行更精确的监控。此外,该方法可用于评估携带任何不平衡染色体变化的发育不良或赘生性克隆的数量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号